<DOC>
	<DOCNO>NCT01070628</DOCNO>
	<brief_summary>The purpose study confirm dose level dose frequency utilise new Stalevo strength would result stable levodopa plasma level . Therefore , anticipate low dose Stalevo administer first high dose Stalevo , would result equally high levodopa maximum concentration value ( Cmax ) dose throughout day compare Cmax first dose .</brief_summary>
	<brief_title>Levodopa Concentration Profile With Stalevo 75/125 mg</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Good general health ascertain detailed medical history , laboratory physical examination . Finnish speaking male female , 1870 year age inclusive . Normal weight define body mass index ( BMI ) 18.530.0 kg/m2 ( inclusive ) ( BMI = weight/height2 ) . Weight least 50.0 kg . Regular intestinal transit ( recent history recurrent constipation , diarrhoea , intestinal problem ) . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disease judge investigator . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . As exception , contraceptives hormone replacement therapy allow . Intake medication could affect outcome study . Any clinically significant abnormal laboratory value physical finding ( include electrocardiogram [ ECG ] ) vital sign ) may interfere interpretation test result cause health risk subject he/she participates study , judge investigator . Orthostatic hypotension ; systolic diastolic BP heart rate HR 3 minute supine position 3 minute stand : decrease ≥ 20 mmHg systolic BP decrease ≥ 10 mmHg diastolic BP . Strong tendency motion sickness . Known hypersensitivity active substance ( ) excipients drug . Pregnant lactating female . Females childbearing potential use proper contraception ( hormonal contraception , intrauterine device ( IUD ) surgical sterilization , spermicidal foam/Vagitorie , condom male partner ) . Double method ( mention ) contraception need study . ( Note : woman childbearing potential current sexual relationship include without contraception accord judgement investigator ) . Recent current ( suspect ) drug abuse positive result drug abuse test . Recent current alcohol abuse ( regular drinking 21 unit per week male 16 unit per week female [ 1 unit = 4 cl spirit equivalent ] ) . Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product stay study centre . Use caffeine contain beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage study centre . Blood donation loss significant amount blood within 90 day prior first study treatment administration . Administration another investigational treatment within 90 day prior first study treatment administration . Unsuitable vein repeat venipuncture cannulation . Predictable poor compliance inability communicate well study centre personnel . Inability participate treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>